Clinical endpoints in trials of drugs for cancer: time for a rethink?
Koopmans
P P
PP
Department General Internal Medicine, University Medical Center St Radboud, Nijmegen, Netherlands. p.koopmans@aig.azn.nl
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D017277:Drug Approval; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010358:Patient Participation; D016896:Treatment Outcome
D000970:Antineoplastic Agents